Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCarolina Behavioral Hypoglossal Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentCarolina Behavioral Health AlliancePolicy NC.CP.MP.180

    Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy NC.CP.MP.180 alerts

    Get alerted when Policy NC.CP.MP.180 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage criteria for implantable hypoglossal nerve stimulation, including the Genio System and Inspire Upper Airway Stimulation System, for selected patients with moderate to severe obstructive sleep apnea. It also addresses drug-induced sleep endoscopy performed to evaluate candidacy for hypoglossal nerve stimulation.

    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyImplantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    Policy CodePolicy NC.CP.MP.180
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document that all applicable device-specific medical necessity criteria and contraindication screens are satisfied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15–65Genio AHI range

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15–100
    Inspire AHI range
    ≤32Genio BMI limit
    ≤40Inspire BMI limit
    25%Central/mixed apnea limit
    24 monthsPSG recency

    Medical Necessity and Coverage Criteria

    Genio System

    Covered as medically necessary when the request is for the Genio System and all of the following criteria are met, with no listed contraindication.

    Genio eligibility

    • Patient and diagnostic criteria

      • Age: Member is age 22 years or older.≥ 22 years
      • BMI is no greater than 32 kg/m².≤ 32 kg/m²
      • Recent PSG: Polysomnography was performed within 24 months of the first consultation for implantation.Within 24 months
      • OSA severity: Diagnosis is moderate to severe obstructive sleep apnea.AHI ≥ 15 and ≤ 65
      • Cricomental space is positive.≥ 0 cm
      • Positional disease or positional therapy

        • Non-supine AHI exceeds 10 events on the screening PSG.> 10 events
        • Positional therapy was not tolerated, failed, or refused.
    • Failure, refusal, or intolerance of standard care

      • Treatment outcome

        • Persistent OSA despite PAP: Unable to eliminate OSA despite PAP use.AHI > 15 despite PAP usage
        • Unable to use PAP at least five nights per week, with use defined as more than four hours per night.At least five nights/week and > 4 hours/night defines use
        • Unwilling to use PAP: Member initiated PAP therapy and subsequently discontinued it by choice.
    • No contraindications: None of the Genio contraindications are present.

      Contraindications include combined central and mixed apneas over 25% of total AHI; a functional, structural, medical, or additional sleep-disorder condition interfering with implantation, activation, or continued use; an active implantable device susceptible to unintended interaction; pregnancy, planned pregnancy, or breastfeeding; and any condition or procedure compromising neurological control of the upper airway.

    Inspire Upper Airway Stimulation System

    Covered as medically necessary when the request is for the Inspire Upper Airway Stimulation System, BMI is no greater than 40 kg/m², polysomnography was performed within 24 months of the first implant consultation, one qualifying age pathway is met, and no listed contraindication is present.

    Inspire eligibility

    • BMI is no greater than 40 kg/m².≤ 40 kg/m²
    • Recent PSG: Polysomnography was performed within 24 months of the first consultation for implantation.Within 24 months
    • Age-specific pathway

      • Adults age 22 years or older: Member is age 22 years or older and has moderate to severe obstructive sleep apnea with failure or intolerance of PAP treatment.

    Drug-Induced Sleep Endoscopy

    Drug-induced sleep endoscopy is medically necessary when completed to evaluate the appropriateness of a hypoglossal nerve stimulation device.

    DISE evaluation: The procedure is medically necessary when performed to evaluate candidacy or appropriateness for hypoglossal nerve stimulation.

    Hypoglossal nerve stimulation is excluded when device-specific contraindications are present. These include a combined central and mixed apnea burden of more than 25% of total AHI, upper-airway anatomical findings that compromise stimulation (including complete concentric collapse of the soft palate), or conditions that compromise neurological control of the upper airway.

    Coverage is also excluded for an active implantable device that may interact with the requested system, inability to operate the device or obtain necessary assistance, pregnancy or planned pregnancy, and other device-specific restrictions. For Inspire, requests are excluded when MRI is required outside the device’s MR Conditional labeling or when rhabdomyolysis is present. Genio requests may also be excluded for functional, structural, medical, or additional sleep-disorder conditions that interfere with implantation, activation, or continued use.

    Coding and Eligibility Parameters

    CPT CodesCPT
    42975Drug-induced sleep endoscopy, with dynamic evaluation of velum, pharynx, tongue base, and larynx for evaluation of sleep-disordered breathing, flexible, diagnostic.
    64582*Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    64583*Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator.
    64584*Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    64568Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
    64569Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator.
    HCPCS CodesHCPCS
    C1767Generator, neurostimulator (implantable), nonrechargeable.
    C1778Lead, neurostimulator (implantable).
    C1787Patient programmer, neurostimulator.
    L8679Implantable neurostimulator, pulse generator, any type.
    L8680Implantable neurostimulator electrode, each.
    L8681Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only.
    L8686Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
    Genio age
    Minimum ageAge ≥ 22 years
    DeviceGenio System
    Eligibility contextRequired for Genio implant candidacy
    Genio BMI
    Maximum BMIBMI ≤ 32 kg/m²
    DeviceGenio System
    Eligibility contextRequired for Genio implant candidacy

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Device-Specific Eligibility

    Obtain prior authorization before implantation of a Genio or Inspire hypoglossal nerve stimulation system. Submit device-specific clinical documentation demonstrating that the applicable age, BMI, PSG timing, OSA severity, treatment-history, anatomical/functional evaluation, and contraindication criteria are satisfied.

    • Identify the requested device: Genio System or Inspire Upper Airway Stimulation System.
    • Include the qualifying PSG, AHI, BMI, age, prior-treatment, and candidacy-assessment records required for the requested device.
    • Document that drug-induced sleep endoscopy (DISE) was completed when used to evaluate appropriateness for hypoglossal nerve stimulation.
    Step Therapy

    Genio: Prior Standard-of-Care Treatment

    For Genio requests, document failure, refusal, or intolerance of current standard-of-care treatment, including lifestyle modifications, PAP, oral appliances, and pharmacotherapy. The record must describe the applicable PAP outcome: persistent OSA despite use, inability to use PAP, or unwillingness to continue PAP after initiating therapy.

    Clinical Background

    Obstructive sleep apnea (OSA) occurs when the upper airway repeatedly collapses during sleep, causing obstructive apneas and hypopneas. The condition may contribute to daytime sleepiness, impaired function, metabolic dysfunction, cardiovascular disease, and mortality. Positive airway pressure (PAP) is the primary treatment, but acceptance and adherence can limit its effectiveness.

    Hypoglossal nerve stimulation is an alternative or second-line treatment for carefully selected patients with moderate to severe OSA who have not benefited from or cannot tolerate PAP. An implantable system detects respiratory effort and delivers stimulation to the hypoglossal nerve during inspiration to help maintain upper-airway patency. Candidacy requires objective confirmation of sleep-disordered breathing and satisfaction of applicable anatomical, age, BMI, and other device-specific criteria.

    Policy Definitions

    Cricomental space
    MeasurementDistance between the neck and the bisection of a line from the chin to the cricoid membrane
    Head positionHead in a neutral position
    Genio criterionCricomental space must be positive (≥ 0 cm)
    PAP use
    Genio definition of inabilityPAP use on fewer than five nights per week
    Definition of useMore than four hours per night
    Inspire wordingUse on fewer than or not greater than five nights per week, with more than four hours per night defining use
    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyImplantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    Policy CodePolicy NC.CP.MP.180
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document that all applicable device-specific medical necessity criteria and contraindication screens are satisfied.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Eligibility ParametersAuthorization, Documentation, and Denial RisksClinical BackgroundPolicy Definitions
    AHI ≥ 15 and ≤ 100

    PAP treatment criteria may be met by inability to eliminate OSA despite PAP, inability to use PAP, or unwillingness to use PAP.

  1. Age 18 to 21 years: Member is age 18 to 21 years, has moderate to severe obstructive sleep apnea, adenotonsillectomy is contraindicated or ineffective, PAP has failed or was not tolerated despite attempts to improve usage, and all other standard-of-care alternative or adjunctive therapies have been considered.AHI ≥ 15 and ≤ 100
  2. Down syndrome age 13 to 18 years: Member has Down syndrome, is age 13 to 18 years, has moderate to severe obstructive sleep apnea, adenotonsillectomy is contraindicated or ineffective, PAP has failed or was not tolerated despite attempts to improve usage, and all other standard-of-care alternative or adjunctive therapies have been considered.AHI > 10 and < 50
  3. No contraindications: None of the Inspire contraindications are present.

    Contraindications include combined central and mixed apneas over 25% of total AHI; anatomical findings compromising stimulation, such as complete concentric collapse of the soft palate; compromised neurological control of the upper airway; inability to operate the device remote or lack of necessary assistance; pregnancy or plans to become pregnant; an implantable device susceptible to unintended interaction; MRI needs outside MR Conditional labeling; and rhabdomyolysis.

  4. Genio AHI
    Minimum AHIAHI ≥ 15
    Maximum AHIAHI ≤ 65
    OSA severityModerate to severe obstructive sleep apnea
    Genio cricomental space
    Minimum measurement≥ 0 cm
    AssessmentCricomental space must be positive
    DeviceGenio System
    Genio non-supine AHI
    Screening PSG thresholdNon-supine AHI > 10 events
    ExceptionRequirement is also met when positional therapy was not tolerated, failed, or refused
    Study typeScreening polysomnography (PSG)
    Inspire BMI
    Maximum BMIBMI ≤ 40 kg/m²
    DeviceInspire Upper Airway Stimulation System
    Eligibility contextRequired for Inspire implant candidacy
    Inspire AHI, age 22 years or older
    Minimum AHIAHI ≥ 15
    Maximum AHIAHI ≤ 100
    Applicable ageAge 22 years or older
    Inspire AHI, age 13 to 21 years
    Ages 18–21AHI ≥ 15 and ≤ 100
    Down syndrome, ages 13–18AHI > 10 and < 50
    Additional pathway requirementsFor both pathways, adenotonsillectomy must be contraindicated or ineffective, PAP must have failed or not been tolerated despite attempts to improve use, and other standard-of-care alternative or adjunctive therapies must have been considered
    Central and mixed apnea burden
    Maximum combined burden≤ 25% of total AHI
    Apnea typesCentral and mixed apneas
    ApplicabilityApplies to Genio and Inspire candidacy
    Polysomnography timing
    Required timingPSG performed within 24 months
    Reference pointBefore the first consultation for the hypoglossal nerve stimulator implant
    DocumentationThe PSG must support the qualifying AHI range for the requested device and age group
    • Failure to eliminate OSA: AHI remains >15 despite PAP usage.
    • Inability to use PAP: use is not achieved at least five nights per week, with usage defined as >4 hours per night.
    • Unwillingness to use PAP: the member initiates PAP and subsequently discontinues it by choice.

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: info

    Unsupported block type: info

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Hypoglossal nerve stimulation
    Treatment typeImplantable upper-airway stimulation treatment
    System functionDetects respiratory effort and delivers stimulation to the hypoglossal nerve during inspiration
    Therapeutic purposeHelps maintain airway patency